Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: The impact of pathologic response on long-term results

Tumori

Volumn 82, Issue 5, 1996, Pages 463-469

  Scattoni, Vincenzo ^a   Bolognesi, Angelo ^a   Cozzarini, Cesare ^a   Francesca, Francesco ^a   Grasso, Marco ^a   Galli, Laura ^a   Torelli, Tullio ^b   Campo, Biagio ^b   Villa, Eugenic ^a   Rigatti, Patrizio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Ospedale Predabissi   (Italy)

Author keywords

bladder cancer; cisplatin; cystectomy; methotrexate; neoadjuvant chemotherapy; vinblastine

Indexed keywords

CISPLATIN; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROGNOSIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; VOMITING;

EID: 12644315023     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169608200511     Document Type: Article

References (30)

1. Dirix L.Y., Van Oosterom A.T.: Neoadjuvant and adjuvant theraphy for invasive bladder tumor. Eur. J. Cancer., 27: 326-330, 1991.
2. Dreicer R., Kollmorgen T.A., Smith R.F., Williams R.D.: Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term follow-up. J. Urol., 150: 849-852, 1993.
3. Droller M.J.: Bladder cancer. In: Urologic Oncology, Grahm S.D. (Ed.), pp. 293-321, Raven Press, New York, 1986.
4. Ghersi D., Stewart L.A., Palmar M.K.B., Coppin C., Martinez-Pineiro J., Raghavan D., Wallace M.A. (Advanced bladder cancer overview collaboration): Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Br. J. Urol., 75: 206-213, 1995.
5. Harker W.G., Meyers F.J., Frehia F.S., Palmer J.M., Shorliffe L.D., Hannigan J.F., McWhirter K.M., Torti F.M.: Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northen California Oncology Group Study. J. Clin Oncol., 3: 1463-1470, 1985.
6. Hatcher P.A., Hahn R.G., Richardson R.L., Zincke H.: Neoadjuvant chemotherapy for invasive bladder carcinoma: disease outcome and bladder preservation and relationship to local tumor response. Eur. Urol., 25: 209-215, 1994.
7. Herr H.W.: Transurethral resection in regionally advanced bladder cancer. Urol. Clin. North Am., 19: 695-700, 1992.
8. Kaplan E.L., Meier P.: Nonparametric estimation from incomplete observations. J. Am. Stat. Ass., 53: 457, 1958.
9. Lerner S.P., Skinner E., Skinner D.G.: Radical cystectomy in regionally advanced bladder cancer. Urol. Clin. North. Am., 19: 713-723, 1992.
10. Logothetis C.J., Dexeus F.H., Finn L.: A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin Oncol., 8: 1050-1055, 1990.
11. Maffezzini M., Torelli T., Villa E., Corrada P., Bolognesi A., Leidi G.L., Rigatti P., Campo B.: Systemic preoperative chemotherapy with cisplatin, methotrexate and vinblastine for locally advanced bladder cancer: local tumor response and early follow-up results. J. Urol., 145: 741-743, 1991.
12. Mantel N.: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163, 1966.
13. Martinez-Piñeiro J.A., Gonzalez Martin M., Arocena F., Flores N., Roncero C.R., Portillo J.A., Escudero A., Cruz F.J., Isorna S.: Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase II study. J. Urol., 153: 964-973, 1995.
14. Mead G.M.: Bladder cancer. Curr. Opinion Oncol., 66: 543-548, 1990.
15. Pagano F., Bassi P.F., Galetti T.P, Meneghino A., Milani C., Arbitrani W., Garbeglio A.: Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J. Urol., 145: 45-50, 1991.
16. Prout G.R., Griffin P.P., Shipley W.U.: Bladder cancer as a systemic disease. Cancer, 43: 2532-2539, 1979.
17. Scher H., Herr H., Sternberg C., Fair W., Bosl G., Morse M., Sogani P., Watson R., Dershaw D., Reuter V., Curley T., Vaughan E.D. Jr., Whitmore W., Yagoda A.: Neoadjuvant chemotherapy for invasive bladder cancer: experience with the M-VAC regimen. Br. J. Urol., 64: 250-256, 1989.
18. Scher H.I., Yagoda A., Herr H.W., Sternberg C.N., Bosl G., Morse M.J., Sogani P.C., Watson R.C., Dershaw D.D., Reuter V., Geller N., Hollander P.S., Vaughan E.D. Jr., Whitmore W.F. Jr., Fair W.R.: Neoadjuvant M-VAC (methotrexate, vinblatine, doxorubicin and cisplatin) effect on the primary bladder lesion. J. Urol., 139: 470-474, 1988.
19. Scher H.I.: Systemic chemotherapy in regionally advanced bladder cancer: theoretical considerations and results. Urol. Clin. North. Am., 19: 747-759, 1992.
20. Schultz P.K., Herr H.W., Zhang Z.F., Bajorin D.F., Seidman A., Sarkis A., Fair W.R., Scherr D., Bosl G.J., Scher H.I.: Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J. Clin Oncol., 12: 1394-1401, 1988.
21. See W.A., Fuller J.R.: Staging of advanced bladder cancer: current concepts and pitfalls. Urol. Clin. North Am., 19: 663-683, 1992.
22. Skinner D.G., Lieskovsky G.: Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J. Urol., 131: 1069-72, 1984.
23. Soloway M.S., Lopez A.E., Patel J., Lu Y.: Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer, 73: 1926-31, 1994.
24. Splinter T.A.W., Scher H.I., Denis L., Bukowski R., Simon S., Klimberg I., Soloway M., Volgelzang N.J., Van Tinteren H., Herr H.: The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J. Urol., 147: 606-608, 1992.
25. Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Herr H.W., Morse M.J.: M-VAC (methotrexate, vinblatine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol., 139: 461-469, 1988.
26. Tannock I., Gospodarowicz M., Connolly J., Jewett M.: M-VAC (methotrexate, vinblatine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J. Urol., 142: 289-292, 1989.
27. Thrasher J.B., Crawford E.D.: Current management of invasive and metastatic transitional cell carcinoma of the bladder. J. Urol., 149: 957-972, 1993.
28. Walther P.J.: Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status. Sem. Urol., 11: 227-234, 1993.
29. Whale S.M., Williams R.D., Gerstbrein J.J., Rosenberg S.J., Henry K.M.: CMV chemotherapy for extensive urothelial carcinoma. World. J. Urol., 6: 158, 1988.
30. Williams S.D., Birch R., Einhorn L.H.: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med., 316: 1435-1440, 1987.